Systemic administration of the gene therapy scAAV2/8-LP1-hFIXco to patients with severe haemophilia B led to stable therapeutic expression of the factor IX gene over 8 years without evidence of late toxicities from treatment, according to a long-term follow-up study.
Treatment with ramucirumab, a human IgG1 monoclonal antibody, significantly improves overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) in both Asians and non-Asians, based on a pooled analysis of REACH* and REACH-2** studies presented at ESMO Asia 2018.
Treatment with the combination of the DAAs* glecaprevir and pibrentasvir led to sustained virological response (SVR) in a majority of patients with chronic hepatitis C virus (HCV) infection genotype 5 or 6, according to the phase IIIB ENDURANCE-5,6** trial.
Treatment with the tyrosine kinase inhibitor cabozantinib led to improved tumour response, in terms of target lesion regression, alpha-fetoprotein (AFP) response, and time to disease progression compared with placebo in patients with advanced hepatocellular carcinoma (HCC) who had prior treatment with sorafenib, according to the CELESTIAL* trial presented at ESMO Asia 2018.
The patient profiles of individuals diagnosed with hepatocellular carcinoma (HCC) vary depending on whether the cause of HCC is hepatitis B virus (HBV) infection or cryptogenic, a Singapore study found.
Close monitoring is necessary in chronic hepatitis B (CHB) gravidas with high viraemia (>6 log10 IU/mL), suggests a recent study, adding that extended antiviral therapy is recommended to mothers whose baseline viraemia is >7 log10 IU/mL for higher serological response.
The drug combination comprising gemcitabine, cisplatin, and S-1 (GCS) led to significant survival benefits compared with the standard dual chemotherapy regimen of gemcitabine and cisplatin (GC) among patients with advanced biliary tract* cancer (BTC), according to results of the KHB01401–MITSUBA** trial presented at ESMO 2018.
Patients with nonalcoholic fatty liver disease (NAFLD)-related hepatocellular carcinoma (HCC) suffer from higher surgical morbidity and posthepatectomy liver failure, according to a new Singapore study.
The trend in liver disease-related mortality in individuals with HIV has changed, with a reduction in the incidence of viral hepatitis-related deaths and an increase in non-alcoholic fatty liver disease (NAFLD)-related deaths, according to a study presented at the International Liver Congress™ (ILC 2019).